Literature DB >> 29620155

Differential expression of Oct3/4 in human breast cancer and normal tissues.

Feng-Qi Zhao1, Yogi Misra1, Da-Biao Li1, Marilyn P Wadsworth2, David Krag3, Donald Weaver2, Joseph Tessitore2, Da-Wei Li4, Guo Zhang1, Qing Tian1, Katie Buss1.   

Abstract

Oct3/4, a transcription factor specifically expressed in mammalian totipotent embryonic stem and germ cells, has a critical role in the regulation and maintenance of pluripotency and self-renewal. However, reactivation of Oct3/4 expression is observed in several human breast cancer cell lines, but not in non‑malignant cells. To examine Oct3/4 expression in human primary breast carcinomas and normal breast tissues, we obtained breast tumor tissues from 28 patients and normal breast tissues from 9 women. According to quantitative polymerase chain reaction, all of the tumor tissues, irrespective of tumor type or clinicopathological status, expressed Oct3/4 mRNA at 10- to 100- fold higher levels than that in the normal breast tissues. Expression of the Oct3/4 protein in tumors was confirmed by western blot analysis and immunofluorescent staining. Additionally, rapid amplification of cDNA ends and DNA sequencing revealed expression of multiple Oct4 gene transcripts from chromosome 6 (POU5F1) in normal breast tissues and the non‑malignant breast epithelial cell line MCF‑10A; by contrast, the breast tumors and malignant breast cancer cell line MCF‑7 predominantly expressed transcripts of an Oct4-like gene (POU5F1B) from chromosome 8, which was termed Oct3 in the current study. The deduced amino acid sequences of full-length Oct3 and Oct4 are 96% identical. The findings of the current study indicated that Oct3, rather than Oct4, may serve as a novel clinical marker and a potential target for gene-specific therapy of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29620155     DOI: 10.3892/ijo.2018.4341

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  The combined restoration of miR-424-5p and miR-142-3p effectively inhibits MCF-7 breast cancer cell line via modulating apoptosis, proliferation, colony formation, cell cycle and autophagy.

Authors:  Narges Dastmalchi; Reza Safaralizadeh; Seyed Mahdi Banan Khojasteh; Mahdi Abdoli Shadbad; Mohammad Ali Hosseinpourfeizi; Shirin Azarbarzin; Ali Rajabi; Behzad Baradaran
Journal:  Mol Biol Rep       Date:  2022-06-06       Impact factor: 2.742

2.  Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma.

Authors:  Kyle T Siebenthall; Chris P Miller; Jeff D Vierstra; Julie Mathieu; Maria Tretiakova; Alex Reynolds; Richard Sandstrom; Eric Rynes; Eric Haugen; Audra Johnson; Jemma Nelson; Daniel Bates; Morgan Diegel; Douglass Dunn; Mark Frerker; Michael Buckley; Rajinder Kaul; Ying Zheng; Jonathan Himmelfarb; Hannele Ruohola-Baker; Shreeram Akilesh
Journal:  EBioMedicine       Date:  2019-03-01       Impact factor: 8.143

3.  Germline copy number variations in BRCA1/2 negative families: Role in the molecular etiology of hereditary breast cancer in Tunisia.

Authors:  Maroua Boujemaa; Yosr Hamdi; Nesrine Mejri; Lilia Romdhane; Kais Ghedira; Hanen Bouaziz; Houda El Benna; Soumaya Labidi; Hamza Dallali; Olfa Jaidane; Sonia Ben Nasr; Abderrazek Haddaoui; Khaled Rahal; Sonia Abdelhak; Hamouda Boussen; Mohamed Samir Boubaker
Journal:  PLoS One       Date:  2021-01-27       Impact factor: 3.240

4.  Novel Variant of OCT4, Named OCT4B5, is Highly Expressed in Human Pluripotent Cells.

Authors:  Majid Mehravar; Ensieh M Poursani
Journal:  Stem Cell Rev Rep       Date:  2020-11-25       Impact factor: 5.739

Review 5.  An Overview on the Complexity of OCT4: at the Level of DNA, RNA and Protein.

Authors:  Majid Mehravar; Fatemeh Ghaemimanesh; Ensieh M Poursani
Journal:  Stem Cell Rev Rep       Date:  2021-01-02       Impact factor: 6.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.